Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

José Rodrigues Pereira; Rebecca Cheng; Mauro Orlando; Joo-Hang Kim; Helen Barraclough

doi:10.1007/s40268-013-0032-6

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Drugs in R&D ◽

10.1007/s40268-013-0032-6 ◽

2013 ◽

Vol 13 (4) ◽

pp. 289-296 ◽

Cited By ~ 15

Author(s):

José Rodrigues Pereira ◽

Rebecca Cheng ◽

Mauro Orlando ◽

Joo-Hang Kim ◽

Helen Barraclough

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3-3 ◽

Cited By ~ 70

Author(s):

R. Pirker ◽

A. Szczesna ◽

J. von Pawel ◽

M. Krzakowski ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdn774 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1249-1256 ◽

Cited By ~ 43

Author(s):

E.H. Tan ◽

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

U. Gatzemeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

O-51 Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): analyses in elderly patients

Lung Cancer ◽

10.1016/s0169-5002(03)91709-0 ◽

2003 ◽

Vol 41 ◽

pp. S18 ◽

Cited By ~ 18

Author(s):

Chandra P. Belani ◽

Frank V. Fossella

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

Lung Cancer ◽

10.1016/s0169-5002(05)80945-6 ◽

2005 ◽

Vol 49 ◽

pp. S235 ◽

Cited By ~ 9

Author(s):

C. Belani ◽

J. von Pawel ◽

A. Pluzanska ◽

V. Gorbounova ◽

E. Kaukel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

Annals of Oncology ◽

10.1093/annonc/mdy292.005 ◽

2018 ◽

Vol 29 ◽

pp. viii496 ◽

Cited By ~ 6

Author(s):

M. Seike ◽

A. Inoue ◽

S. Sugawara ◽

S. Morita ◽

Y. Hosomi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283155.03863.e7 ◽

2007 ◽

Vol 2 (8) ◽

pp. S340-S341 ◽

Cited By ~ 58

Author(s):

Thomas J. Lynch ◽

Taral Patel ◽

Luke Dreisbach ◽

Michael McCleod ◽

William J. Heim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72038-5 ◽

2009 ◽

Vol 7 (3) ◽

pp. 6 ◽

Cited By ~ 7

Author(s):

A. Inoue ◽

K. Kobayashi ◽

M. Maemondo ◽

S. Sugawara ◽

S. Oizumi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2017.01.002 ◽

2017 ◽

Vol 18 (4) ◽

pp. e289-e296 ◽

Cited By ~ 10

Author(s):

Cheol-Kyu Park ◽

In-Jae Oh ◽

Kyu-Sik Kim ◽

Yoo-Duk Choi ◽

Tae-Won Jang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text